

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	5580046
<b>Application Number:</b>	10559982
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	6583
<b>Title of Invention:</b>	Methods for treatment of parkinson's disease
<b>First Named Inventor/Applicant Name:</b>	Fariello Ruggero
<b>Customer Number:</b>	37509
<b>Filer:</b>	Daniel M. Becker/Paula Hurley
<b>Filer Authorized By:</b>	Daniel M. Becker
<b>Attorney Docket Number:</b>	373987-011US (102895)
<b>Receipt Date:</b>	24-JUN-2009
<b>Filing Date:</b>	02-FEB-2006
<b>Time Stamp:</b>	16:01:32
<b>Application Type:</b>	U.S. National Stage under 35 USC 371

### Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$ 180
RAM confirmation Number	2321
Deposit Account	502778
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

## File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1		IDS_3.pdf	578820 c056d988134f18f5442988f73f0159ac1342dc	yes	11
Multipart Description/PDF files in .zip description					
	Document Description		Start		End
	Transmittal Letter		1		4
	Information Disclosure Statement (IDS) Filed (SB/08)		5		11
Warnings:					
Information:					
2	NPL Documents	Andringa_TCH346.pdf	7656602 88f110794208569d3da046eeea308732bab19482	no	13
Warnings:					
The page size in the PDF is too large. The pages should be 8.5 x 11 or A4. If this PDF is submitted, the pages will be resized upon entry into the Image File Wrapper and may affect subsequent processing					
Information:					
3	NPL Documents	BenedettiAnticonvulsant.pdf	670245 086d300a35cd7773f8b6fac2ed228728b3c9395	no	6
Warnings:					
Information:					
4	NPL Documents	Calne_Manganism.pdf	1889043 335cc98f63c748b9cdd6e1132eb3bc752ff2d847	no	4
Warnings:					
Information:					
5	NPL Documents	Chaudhuri_International.pdf	5186140 352556ce12c7406020f4b4b46c4b72f640015e6e	no	8
Warnings:					
Information:					
6	NPL Documents	Chaudhuri_Metric.pdf	7026112 b2a00812a155668f55ec32926c8d1d7f8ba9ffccde	no	11
Warnings:					
Information:					
7	NPL Documents	Cho_Model.pdf	1594615 907f83e9b6e4c2f8b6407548bc72282525c51209	no	4

Warnings:

Information:					
8	NPL Documents	Olanow_CURRICULUM_VITAE.pdf	325321	no	103
			fbac2d8ba0b145400dc540977ae041616c4954		
Warnings:					
Information:					
9	NPL Documents	Dubois_Movement.pdf	7631988	no	11
			52ae5c5d59b081ee134c617764b1fa3041292209		
Warnings:					
Information:					
10	NPL Documents	Emre_Clinical.pdf	14056640	no	19
			fbef06a092daf71482011e0b51c7566101055f		
Warnings:					
Information:					
11	NPL Documents	Fahn_Levodopa.pdf	4172282	no	11
			05c10306c5e00fba0077248289e3a281c4b11		
Warnings:					
Information:					
12	NPL Documents	Freeman_UseofPlacebo.pdf	2440921	no	5
			bde6a0f73e3e0c7a03b54b1a5102af773e49b7		
Warnings:					
Information:					
13	NPL Documents	Freeman_Bilateral.pdf	4748141	no	11
			e70f9600545ee3b366ded62ae1ca909e5b3885		
Warnings:					
Information:					
14	NPL Documents	Germano_Unilateral.pdf	3895579	no	8
			6e047ecdae4750285614bcd82d5ee91070043ba4f		
Warnings:					
Information:					
15	NPL Documents	Goetz_MovementDisorder_Process.pdf	5289205	no	7
			ec081d485e0d4d70ba3a32b78a1c0eaf27656		
Warnings:					
Information:					
16	NPL Documents	Goetz_Sarizotan.pdf	5386115	no	8
			7c08f057434118559e0b8c5d377aaf5c09ee902		

<b>Warnings:</b>					
<b>Information:</b>					
17	NPL Documents	Goetz_MovementDisorder_Scale.pdf	11263322 bf1a756a1e718ba72a3f9bbe5c08b1d03 86d1ef	no	42
<b>Warnings:</b>					
<b>Information:</b>					
18	NPL Documents	Good_Neuromelanin.pdf	1502116 c104bcc38b171718b7a57ed6d883d53c7 442b3	no	4
<b>Warnings:</b>					
<b>Information:</b>					
19	NPL Documents	Huang_Progression.pdf	2018295 c9724b1b7d944bc9d8f8b5bdc05674db1 15d3	no	6
<b>Warnings:</b>					
<b>Information:</b>					
20	NPL Documents	Hauser_Longterm.pdf	6788693 a181b416464546eac2db66c1b60e39f7f e08f	no	9
<b>Warnings:</b>					
<b>Information:</b>					
21	NPL Documents	Hauser_Blood.pdf	2395531 513cda567d2d8a569a394b52187ab8a9f c1a1f	no	5
<b>Warnings:</b>					
<b>Information:</b>					
22	NPL Documents	Jenner_Oxidative.pdf	5299501 381fa116861140e11c366b8f79a24a9054 bcba	no	11
<b>Warnings:</b>					
<b>Information:</b>					
23	NPL Documents	Koller_High.pdf	2697577 9f8ae9a020a12b546ca73d6a20a065e103 bbdb	no	8
<b>Warnings:</b>					
<b>Information:</b>					
24	NPL Documents	Kordower_Dopaminergic.pdf	3193845 171c593362aef874805cd878bc780e514d d8a5	no	6
<b>Warnings:</b>					
<b>Information:</b>					
25	NPL Documents	Kordower_FetalGrafting.pdf	2775146 62a0dab8abaf92262a2c86f980265ed2a3f 0d53	no	7

<b>Warnings:</b>					
<b>Information:</b>					
26	NPL Documents	Kordower_Neuropathologic.pdf	3264799 d99c356fb99ab1e9551378b84d72170d11e4d538	no	7
<b>Warnings:</b>					
<b>Information:</b>					
27	NPL Documents	KordowerFunctional.pdf	18722970 dc3880f4e6f6b8247bd40949326c143a981cde6	no	28
<b>Warnings:</b>					
<b>Information:</b>					
28	NPL Documents	Kordower_FetalNigral.pdf	5404713 fc21d49eed51cc89b74127b465a19f1ccafcc86	no	11
<b>Warnings:</b>					
<b>Information:</b>					
29	NPL Documents	Kordower_Transplanted.pdf	2050476 ab3b32354ac58f90c7c3f85418c66c4092ac98da	no	4
<b>Warnings:</b>					
<b>Information:</b>					
30	NPL Documents	Kordower_Lewy.pdf	1683337 6e6b851274ab289636d2b0f8b6f5c18ee6cc5d16	no	3
<b>Warnings:</b>					
<b>Information:</b>					
31	NPL Documents	Lieberman_Multicenter.pdf	2777346 cca7740bb015ba00128f723d93dc449eb92896db	no	6
<b>Warnings:</b>					
<b>Information:</b>					
32	NPL Documents	Marks_Safety.pdf	6289726 f9c5fc559c658fba88a4b86d7b0aeb91f8d8d	no	9
<b>Warnings:</b>					
<b>Information:</b>					
33	NPL Documents	Martinez_Martin_Prevalence.pdf	4148646 e079abdc9510d53d4c1c724a7e5274131a7bdf1c5	no	7
<b>Warnings:</b>					
<b>Information:</b>					
34	NPL Documents	McNaught_Proteasomal_dysfunction.pdf	6527371 3dbce68c586af2f261ad398b96c736f818020a8d1	no	13

<b>Warnings:</b>					
<b>Information:</b>					
35	NPL Documents	McNaught_Impairment_ubiquitin.pdf	2922519 3c5981012ab1a6ce818e6e1a5c1d130a;B1018a	no	6
<b>Warnings:</b>					
<b>Information:</b>					
36	NPL Documents	McNaught_Proteasomal_Inhibition_nigral.pdf	2363942 1d4c163a41111992a4c9a90d19ecd506a147d62	no	5
<b>Warnings:</b>					
<b>Information:</b>					
37	NPL Documents	McNaught_Systemic_exposure.pdf	6151264 24d29e617E3d270c4d6d5a8f74d2e03dd70d2	no	14
<b>Warnings:</b>					
<b>Information:</b>					
38	NPL Documents	McNaught_Failure_ubiquitin.pdf	4965482 9b42773a752c5da03ed198ce9d8f1065a5827	no	6
<b>Warnings:</b>					
<b>Information:</b>					
39	NPL Documents	McNaught_Proteasome_Inhibitor-Induced.pdf	2814972 3a9d859b3186aa1a8c7653c15d4f65421d6d	no	5
<b>Warnings:</b>					
The page size in the PDF is too large. The pages should be 8.5 x 11 or A4. If this PDF is submitted, the pages will be resized upon entry into the Image File Wrapper and may affect subsequent processing					
<b>Information:</b>					
40	NPL Documents	Morrison_Program.pdf	21334977 64d8d18b8d8543114ed88c1d4122db69757e795c	no	16
<b>Warnings:</b>					
<b>Information:</b>					
41	NPL Documents	Mytilineou_desmethylselegiline.pdf	1952225 173cd1b1bdc0e7b65d4d463d2c82c9f6d75c	no	3
<b>Warnings:</b>					
The page size in the PDF is too large. The pages should be 8.5 x 11 or A4. If this PDF is submitted, the pages will be resized upon entry into the Image File Wrapper and may affect subsequent processing					
<b>Information:</b>					
42	NPL Documents	Mytilineou_Inhibition.pdf	4416818 d160067b3d8f579d075a3c2c07d5a3815649a4	no	15
<b>Warnings:</b>					

<b>Information:</b>					
43	NPL Documents	Nair_p53Mediates.pdf	7850902 494b6b0bae7c8413db4ee4d975d6c1a76b4e	no	11
<b>Warnings:</b>					
The page size in the PDF is too large. The pages should be 8.5 x 11 or A4. If this PDF is submitted, the pages will be resized upon entry into the Image File Wrapper and may affect subsequent processing					
<b>Information:</b>					
44	NPL Documents	Olanaow_Free.pdf	898978 96d47001cddaa0498fc7a76c03e171d11c4980	no	2
<b>Warnings:</b>					
<b>Information:</b>					
45	NPL Documents	Olanow_Double_blind_Bilatera l_fetal.pdf	5620996 463b31c12171b4015c448ce6c5c29a5c03b588e5	no	12
<b>Warnings:</b>					
<b>Information:</b>					
46	NPL Documents	Olanow_Role_Deep_Brain.pdf	3804774 5D72c6d7967e1e6f81b551ea37ca1f86c118830	no	7
<b>Warnings:</b>					
<b>Information:</b>					
47	NPL Documents	Olanow_ClinicalPattern.pdf	3091194 e01e6c08a0c2d3d80854965d3d8d38079c6d	no	9
<b>Warnings:</b>					
<b>Information:</b>					
48	NPL Documents	Olanow_Fetal_nigral.pdf	3540418 4078234ea831c5564c08ba6a7aef52d1b4749	no	8
<b>Warnings:</b>					
<b>Information:</b>					
49	NPL Documents	Olanow_OpenMulticenter.pdf	1415223 3bd8d796761925e195a90573d361c1e1e9d27x6d	no	6
<b>Warnings:</b>					
<b>Information:</b>					
50	NPL Documents	Olanow_Double_Blind_Pergoli de_Sinemet.pdf	2021956 1dc1fbc53b77113481f408a55f0ac3aac95e	no	6
<b>Warnings:</b>					
<b>Information:</b>					

51	NPL Documents	Olanow_Double_blind_controlled_treatment.pdf	2112108 c7520c15a0554c72c57b099bc160f51cc486c	no	8
<b>Warnings:</b>					
<b>Information:</b>					
52	NPL Documents	Olanow_Multicenter_double_blind.pdf	2935113 b34d8ca718d7b0c0f996c186996a781ad779db	no	8
<b>Warnings:</b>					
<b>Information:</b>					
53	NPL Documents	Olanow_Effect_deprenyl.pdf	2373536 66209f48511a435e96c52b7b848f9ee7b73a35e7f84	no	7
<b>Warnings:</b>					
<b>Information:</b>					
54	NPL Documents	Olanow_Tolcapone_hepatotoxic.pdf	4077621 29cc52aa2496c08bc866db11bb5cd7c6a8d3d	no	5
<b>Warnings:</b>					
<b>Information:</b>					
55	NPL Documents	Olanaw_Tolcapone.pdf	2658130 8d886a0c75b475e4c4b25e11b5200943d1	no	8
<b>Warnings:</b>					
<b>Information:</b>					
56	NPL Documents	Olanow_Double_Blind_Placebo-controlled.pdf	4195678 3d99d0d1262d6d4b8dbd3d241c2a2593128f5b	no	6
<b>Warnings:</b>					
<b>Information:</b>					
57	NPL Documents	Olanow_RandomizedDouble.pdf	4488036 977a785ce88bc5ddc93b2bc893e4e9d07872d1	no	8
<b>Warnings:</b>					
The page size in the PDF is too large. The pages should be 8.5 x 11 or A4. If this PDF is submitted, the pages will be resized upon entry into the Image File Wrapper and may affect subsequent processing					
<b>Information:</b>					
58	NPL Documents	Parkinson_Study_Group_Effect_s_Tocopherol.pdf	3616456 9c3ab8f8f26404ce488c618b6a22f1d3b07e0f7	no	8
<b>Warnings:</b>					
<b>Information:</b>					
59	NPL Documents	Olanow_Introduction.pdf	3172091 d8f8a2bf8f52e57c7946c74dec36a36ec91c3a0f	no	8



**Warnings:****Information:**

60	Fee Worksheet (PTO-875)	fee-info.pdf	30261	no	2
			(B)003492115089c661d4f3c3dFee7974855 (B)00		

**Warnings:****Information:**

Total Files Size (in bytes):		266176849
------------------------------	--	-----------

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

**New Applications Under 35 U.S.C. 111**

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

**National Stage of an International Application under 35 U.S.C. 371**

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

**New International Application Filed with the USPTO as a Receiving Office**

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.